| Andrea I Mamaril, FNP-C | |
|
18051 River Rd Ste 101, Noblesville, IN 46062-7093 | |
| (317) 674-0062 | |
| Not Available |
| Full Name | Andrea I Mamaril |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 18051 River Rd Ste 101, Noblesville, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134879042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 71012336A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleanslate Medical Group Of Indiana Llc | 4880963909 | 63 |
News Archive
"Shell-shocked Chileans struggled to deal with the aftermath of a massive 8.8-magnitude earthquake that ripped through the southern half of the country early Saturday morning," the Wall Street Journal reports.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
The Queen Victoria Hospital, East Grinstead, has been trialling the treatment and has already helped 40 people see again. The hospital has been developing the surgery over the past five years and uses stem cells taken from the patient or a donor to redevelop the cornea, the transparent film at the front of the eye which lets in light.
A new study led by scientists at The Scripps Research Institute is giving researchers a first look at the early stages of brain development in patients with Fragile X syndrome, a disorder that causes mild to severe intellectual disability and is the most common genetic cause of autism spectrum disorder.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
› Verified 8 days ago
| Entity Name | Cleanslate Medical Group Of Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023464294 PECOS PAC ID: 4880963909 Enrollment ID: O20171023001515 |
News Archive
"Shell-shocked Chileans struggled to deal with the aftermath of a massive 8.8-magnitude earthquake that ripped through the southern half of the country early Saturday morning," the Wall Street Journal reports.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
The Queen Victoria Hospital, East Grinstead, has been trialling the treatment and has already helped 40 people see again. The hospital has been developing the surgery over the past five years and uses stem cells taken from the patient or a donor to redevelop the cornea, the transparent film at the front of the eye which lets in light.
A new study led by scientists at The Scripps Research Institute is giving researchers a first look at the early stages of brain development in patients with Fragile X syndrome, a disorder that causes mild to severe intellectual disability and is the most common genetic cause of autism spectrum disorder.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea I Mamaril, FNP-C 18051 River Rd Ste 101, Noblesville, IN 46062-7093 Ph: (317) 674-0062 | Andrea I Mamaril, FNP-C 18051 River Rd Ste 101, Noblesville, IN 46062-7093 Ph: (317) 674-0062 |
News Archive
"Shell-shocked Chileans struggled to deal with the aftermath of a massive 8.8-magnitude earthquake that ripped through the southern half of the country early Saturday morning," the Wall Street Journal reports.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
The Queen Victoria Hospital, East Grinstead, has been trialling the treatment and has already helped 40 people see again. The hospital has been developing the surgery over the past five years and uses stem cells taken from the patient or a donor to redevelop the cornea, the transparent film at the front of the eye which lets in light.
A new study led by scientists at The Scripps Research Institute is giving researchers a first look at the early stages of brain development in patients with Fragile X syndrome, a disorder that causes mild to severe intellectual disability and is the most common genetic cause of autism spectrum disorder.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.
› Verified 8 days ago
Heather Lynn Lutz, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 18051 River Rd Ste 105, Noblesville, IN 46062 Phone: 317-570-7900 Fax: 317-570-2286 | |
Kaitlyn Nicole Dervenis, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 493 Westfield Rd, Noblesville, IN 46060 Phone: 317-363-9788 | |
Krista M Spalding, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 355 Westfield Rd Ste 114, Noblesville, IN 46060 Phone: 317-770-2937 Fax: 317-770-2938 | |
Jacqueline L Seacat, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 865 Westfield Rd, Noblesville, IN 46062 Phone: 317-776-3854 Fax: 317-776-3854 | |
Tracy A Donahue, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 14540 Prairie Lakes Blvd N, Suite 207, Noblesville, IN 46060 Phone: 317-621-2455 Fax: 317-355-6166 | |
Ashley Renee Miller, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 865 Westfield Rd Ste D, Noblesville, IN 46062 Phone: 317-776-3851 Fax: 317-776-3854 | |
Ms. Mary Ann Ruff-troup, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 5695 Pebble Village Ln, Noblesville, IN 46062 Phone: 317-450-7722 |